P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL
暂无分享，去创建一个
Michael J. Hoffmann | E. Nievergall | J. Dürig | C. Scheid | R. Schroers | R. Fenk | D. Tichy | S. Luntz | M. Munder | W. Knauf | C. Khandanpour | N. Weinhold | S. Huhn | U. Bertsch | H. Salwender | M. Raab | E. Mai | K. Weisel | A. Asemissen | M. Hänel | T. Geer | B. Heilmeier | K. Trautmann-Grill | H. Riesenberg | D. Gezer | B. Besemer | C. Mann | M. Klaiber-Hakimi | M. Müller | J. Thomalla | H. Goldschmidt | I. von Metzler | K. Kriegsmann | T. A. W. Holderrried